Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

Of 93 patients with pretreated, BRAFV600 mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n = 45) or after (n = 48) treatment with ipilimumab 3 mg/kg, median overall survival (mOS) from first treatment was 9.9 and 14.5 months, respectively. Among patients treated with a BRAF inhibitor first, mOS from the end of BRAF inhibition was 1.2 months for those who did not complete ipilimumab treatment as per protocol, compared with 12.7 months for those who did (p < .001). Prospective, randomized studies are required to determine the optimal sequencing of ipilimumab and BRAF inhibitors in patients with BRAF-mutated metastatic melanoma.

[1]  M. Weichenthal,et al.  Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[2]  David C. Smith,et al.  Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Wolchok,et al.  Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. , 2013 .

[4]  J. Wolchok,et al.  Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials. , 2013 .

[5]  Dennie T. Frederick,et al.  Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma , 2013, Oncoimmunology.

[6]  J. Wolchok,et al.  Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.

[7]  P. Ascierto,et al.  Do BRAF inhibitors select for populations with different disease progression kinetics? , 2013, Journal of Translational Medicine.

[8]  C. Berking,et al.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.

[9]  Michael B Atkins,et al.  Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.

[10]  J. Sosman,et al.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Ascierto,et al.  Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use , 2012, Journal of Translational Medicine.

[12]  A. Giobbie-Hurder,et al.  Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. , 2012 .

[13]  S. Rosenberg,et al.  CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.

[14]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[16]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[17]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[18]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[19]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[20]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[22]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .